Back to top

vaccines: Archive

Sundeep Ganoria

4 Biotech Stocks Set to Outpace Q2 Earnings Estimates

Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.

NVAXPositive Net Change ARCTPositive Net Change EBSNegative Net Change AXSMPositive Net Change

Zacks Equity Research

Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View

Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.

JNJPositive Net Change MRKPositive Net Change MRNAPositive Net Change CRBUPositive Net Change

Zacks Equity Research

Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View

Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.

AZNPositive Net Change JNJPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates?

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.

NVOPositive Net Change MRKPositive Net Change MRNAPositive Net Change ACADPositive Net Change

Zacks Equity Research

AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales

AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications. Management reaffirms its 2023 guidance.

AZNPositive Net Change JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change

Zacks Equity Research

GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance

GSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK raises guidance for earnings and sales. Shares rise in pre-market trading post the announcement.

GSKPositive Net Change JNJPositive Net Change ALKSPositive Net Change VIRPositive Net Change

Zacks Equity Research

AstraZeneca (AZN) to Report Q2 Earnings: What's in the Cards?

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales, partially offset by lower sales of legacy drugs.

AZNPositive Net Change GSKPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?

We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.

GSKPositive Net Change MRNAPositive Net Change ADCTPositive Net Change ACADPositive Net Change

Zacks Equity Research

Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal

Interim data from a late-stage study, evaluating Merck's (MRK) Keytruda as a combination therapy, met one of its primary endpoints of progression-free survival.

MRKPositive Net Change HOWLPositive Net Change ERASPositive Net Change

Zacks Equity Research

Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine

Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.

AZNPositive Net Change GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Can Eli Lilly's (LLY) Continue its Ride on Obesity Drug Wave?

Lilly (LLY) continues to raise the bar on obesity drugs as latest data show that participants treated with these experimental drugs achieved mean weight reduction of up to 24%.

JNJPositive Net Change PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change

Zacks Equity Research

AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results

While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival.

AZNPositive Net Change NVSPositive Net Change VRTXNegative Net Change ABBVPositive Net Change

Zacks Equity Research

Moderna (MRNA) Submits Filing in EU for Updated COVID-19 Jab

Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. If the filing is approved in the EU, the vaccine will be made available for the fall season.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change